Oncology

Breast cancer survivors with high genetic risk for excess body weight had 15% higher mortality, and required more weekly walking to mitigate inherited risk.

Phase two data show Elenagen combined with gemcitabine significantly prolongs overall survival in platinum resistant ovarian cancer without added safety concerns.

A Phase three trial shows early immunochemotherapy significantly improves survival and enhances CD8 T cell responses in advanced non small cell lung cancer.

Large cohort study shows GLP 1 receptor agonists combined with progestins lower endometrial cancer risk and reduce hysterectomy incidence in women with benign uterine disease.

Phase 2 findings show neoadjuvant pembrolizumab produced a 71% pathological complete response rate in resectable desmoplastic melanoma, with favourable safety and three year follow up outcomes.

A large US registry study found significantly worse one year cancer survival during 2020 and 2021, with an estimated 17 390 excess deaths linked to COVID-19 pandemic disruptions in care.

Quantitative digital pathology revealed distinct morphometric features among mixed odontogenic tumors, suggesting virtual cell analysis may aid diagnosis when conventional histology is inconclusive.

Epigenetic therapy combined with immunotherapy reshaped the tumour microenvironment in platinum-resistant ovarian cancer, promoting inflammatory immune signalling and disease control in half of treated patients.